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Abstract
Background: Presence of lobular intraepithelial neoplasia (LIN) is not routinely reported as part of margin
assessment in breast conservation therapy (BCT) as in ductal carcinoma in situ (DCIS). With new emerging evidence
of LIN as possible precursor lesion, the hypothesis is that LIN at the margin may increase the risk of local
recurrence with BCT. The aim is to determine whether there is an increase incidence of recurrence when LIN is
found at surgical margins on BCT.
Methods: We retrospectively reviewed a total of 1,334 BCT at a single institution in a 10 year period. Inclusion
criteria are positive margin with LIN from primary BCT containing invasive and/or in situ carcinoma with
comparison to the negative control group who had similar diseases with negative margin for LIN.
Results: We identified 38 cases (2.8%) with LIN either lobular carcinoma in situ/atypical lobular hyperplasia (LCIS/
ALH) at a margin on initial BCT with 36% recurrence rate. Of the 38 cases: 5 (13%) were lost to follow-up, 12 (32%)
had no further procedures performed and 21 (55%) had re-excision. Out of 21 patients who had re-excisions, 12
(57%) had residual invasive carcinoma or DCIS, three (14%) had pleomorphic LCIS and 4 (19%) showed residual
classic type LCIS. 71% had significant residual disease (local recurrence) and 29% had no residual disease. A
negative control group consisted of 38 cases. We found two patients with bone or brain metastasis and one local
recurrence. Clinical follow up periods range from 1 to 109 months.
Conclusions: LIN found at a margin on BCT showed a significant recurrent ipsilateral disease. Our study supports
the view that LIN seen at the margin may play a role in recurrence.
Background
Foote and Stewart [1] initially described the entity “lob-
ular carcinoma in situ” (LCIS) in 1941 and described it
as a “precancerous” lesion. At that time, a diagnosis of
LCIS was treated like a cancer by radical mastectomy.
Haagenson et al [2] believed that the term “in situ” was
a misnomer and preferred the term “lobular neoplasia”
in 1978 because LCIS did not appear as a premalignant
lesion but as a marker for increased risk for developing
cancer. This notion was based on his observation that
only 17% of 211 patients with LCIS developed invasive
cancer with a mean follow-up time of 14 years, either
ipsilateral and/or contralateral side of the breast.
Subsequent studies of LCIS which included epidemiolo-
gic data have confirmed that LCIS is a risk factor and
not an obligatory precursor lesion as ductal carcinoma
in situ (DCIS). There is controversy on the management
when lobular neoplasia is found on the core needle
biopsy whether to watch carefully or perform an exci-
sion. The presence of lobular intraepithelial neoplasia
(LIN) at the surgical margin is frequently not reported
as part of the pathology analysis as in DCIS or invasive
cancer for BCT. When DCIS or invasive carcinoma is
found at a surgical margin, re-excision and radiation
therapy is the standard management. However, when
LIN is found at a surgical margin, it is not routinely
reported. No re-excision is done and radiation therapy
is not recommended for LIN unless there is a concomi-
tant invasive carcinoma or DCIS in BCT.
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known as a variant of LCIS which is negative for E-cad-
herin, supporting lobular differentiation. PLCIS may
show central comedo necrosis and a higher nuclear
grade resembling DCIS. PLCIS found at a margin has an
increased recurrence rate when compared to classic
LCIS. Hence it is recommended for re-excision when
the surgical margins are involved with PLCIS on BCT.
A study on PLCIS at a margin and radiation therapy has
yet to be performed and further investigation needs to
be done.
Moreover, recent studies show that LCIS and invasive
lobular carcinoma (ILC) share a similar genetic molecu-
lar biology. New research suggests that there is a genetic
progression of LCIS to an invasive carcinoma and that
the biologic significance of LCIS may be a “field effect”
of this lesion for the development of invasive carcinoma
[3-5]. With this new emerging evidence, there are
increasing concerns regarding the biological significance
of LCIS. The hypothesis is the presence of LCIS compo-
nent associated with invasive carcinoma will increase
the risk of local failure with breast conservation surgery,
especially if LCIS is seen at the surgical margin. Since
LIN at a margin is not mentioned routinely in pathology
reports, it would be challenging to do any follow-up stu-
dies on the biological significance of LIN seen at mar-
gins. At our institution, however, margin assessment
with LIN, both ALH and LCIS, has been routinely noted
as the part of pathology report for the last 10 years. Re-
excision was not mandatory if LIN was found at the sur-
gical margins but left to each individual patient’s deci-
sion based on a careful balanced discussion with the
surgeon. Our hypothesis is that LIN is most likely not
just a risk factor, but a precursor lesion to invasive can-
cer, and that LIN at the surgical margin may have a sig-
nificantly higher recurrence rate over clear margins on
BCT. The purpose of our study was to determine the
recurrence rate of patients who had LIN at the margin
after BCT at a single institution.
Methods
We retrospectively reviewed a total of 1,334 breast sur-
gical excision specimens at a single institution in a 10
year period with a keyword search of “breast, lumpect-
omy, excision, lobular carcinoma in situ (LCIS) and aty-
pical lobular hyperplasia (ALH)” via our Tamtron
Powerpath computer system, after obtaining institutional
review board (IRB) approval. We routinely did not use
LIN terminology and WHO grading of LIN 1, 2 and 3
in our institution. Our terminology composed of ALH,
and LCIS which were the classic type, LCIS with disten-
sion and comedo necrosis with nuclear grade 2 and
pleomorphic LCIS with nuclear grade 3. Our terminol-
ogy can be extracted, however, to WHO classifications:
LIN grade 1 being ALH and LCIS classic type, LIN
grade 2 being LCIS with distension and with or without
comedo necrosis with nuclear grade 2 and LIN grade 3
being pleomorphic LCIS with nuclear grade 3. (See
F i g u r e s1 ,2 ,3 ,4 ,5 ,&6 ) .M o s to ft h ec a s e so fi n v a s i v e
carcinoma had mass lesion on mammogram, ultrasound
and MRI. Most of the cases of pleomorphic LCIS and
DCIS had pleomorphic calcifications on mammogram
without mass lesions. Representative images are shown
in Figures 7, 8, & 9.
A positive group was defined by patients who had a
primary breast conservation surgery containing invasive
mammary carcinoma, DCIS, or LIN, with either LCIS or
ALH seen at the final margin. When LCIS or ALH was
present in the specimen, it was defined as being present
at the final margin if the lesion was described as touch-
ing an inked surface. Margins were defined as close for
invasive carcinoma or DCIS if tumor cells were within 2
mm of an inked margin. We excluded all cases if inva-
sive carcinoma or DCIS was found less than or equal to
2m mf r o mt h ef i n a lm a r g i nf r o mt h ep o s i t i v eg r o u p .
The primary endpoint of the study was local residual
disease or recurrence in the ipsilateral breast. When re-
excision showed residual invasive mammary carcinoma
or DCIS or pleomorphic type LCIS, we defined the indi-
vidual as positive for local recurrence. Patients who had
negative findings, or residual classic LCIS or ALH were
considered as a negative for local recurrence. To match
t h ep o s i t i v eg r o u p ,w es e l e c t e d3 8p a t i e n t sw h oh a d
invasive mammary carcinoma or DCIS in addition to
LIN, but margins negative for all lesions including
LCIS/ALH. This sample of 38 patients was analyzed as a
negative group. Available clinical follow-up was done for
both positive and negative groups.
Figure 1 Classic LCIS (LIN 1). H&E × 40 magnification: Classic type
lobular carcinoma in situ (LCIS) with small monotonous dyshesive
cells expanding terminal ductal lobular unit. LIN 1 by WHO criteria
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Positive group
From a total of 1,334 breast surgical excision specimens,
we identified 38 cases (2.8%) fitting our inclusion cri-
teria for the positive group. Of the 38 cases: 5 (13%)
were lost to follow-up, 12 (32%) had no further proce-
dures performed and 21 (55%) had subsequent pathol-
ogy specimens which consisted of 10 mastectomies, 10
re-lumpectomies, and 1 re-lumpectomy followed by
mastectomy. Of 21 patients with re-excision, 12 (57%)
had residual invasive carcinoma or DCIS, three (14%)
had pleomorphic LCIS, 4 (19%) showed residual classic
type LCIS, one (5%) had contralateral DCIS, and one
(5%) had no residual tumor. Out of 21 patients who had
re-excisions, 71% had significant residual disease (local
recurrence), and 29% had no residual disease on re-exci-
sion. The clinical reasons that prompted re-excision in
21 patients with LCIS at the margin from the initial
breast conservation surgery were not clearly documen-
ted in the medical record. Per surgeons, most of these
patients decided to undergo additional surgeries mainly
due to two factors; LCIS being a risk factor to develop-
ing into cancer in the future and any lesion being “posi-
tive” at the margin in the pathology report are enough
to cause anxiety. Also, some of the patients who had
invasive lobular carcinoma were not detected in a rou-
tine mammogram but additional imaging modality such
as ultrasound and MRI were done to detect the pre-
sence of tumor. And hence, the annual clinical follow-
up studies after BCT would be a financial burden to
Figure 3 Pleomorphic LCIS (LIN 3). H&E × 40 magnification:
Pleomorphic LCIS exhibiting large, dyshesive, and apocrine-like cells.
LIN 3 by WHO criteria
Figure 4 Pleomorphic LCIS (LIN 3). H&E × 40 magnification:
Pleomorphic LCIS exhibiting large, signet ring-like, dyshesive cells.
LIN 3 by WHO criteria
Figure 5 Distended large cell LCIS with necrosis (LIN 2).H & E×
40 magnification: Distended large cell LCIS with central necrosis
and calcifications. Nuclei are less pleomorphic and were considered
LIN 2 by WHO criteria.
Figure 2 Atypical lobular hyperplasia (AHL) (LIN 1).H & E×6 0
magnification: Atypical lobular hyperplasia (ALH) shows similar
nuclear features as classic LCIS but less expansion of terminal ductal
lobular unit
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dual diseases or no recurrence in their clinical follow
up. The median follow up from 12 patients who had no
re-excision was 36 months [mean follow up of 40.1
months], ranging from 1 to 109 months with mammo-
gram follow-up. Hormonal receptor studies were per-
formed on invasive carcinoma or DCIS cases only. We
did not perform hormonal receptors on classic LIN or
pleomorphic LIN cases. However, most of the pleo-
morphic LIN with grade 3 cases had E-cadherin stain.
See Additional file 1.
Negative group
A negative control group consisted of matched 38 cases
with BCT of invasive carcinoma and/or in-situ carci-
noma that also had LIN in the specimen, but with clear
margins. No patients had re-excision from this group.
Both groups were matched to tumor type, stage and
grade, lymph node status and patient age with clinical
follow up in the patient’s medical records. See Addi-
tional File 2.
From the negative control group, we found two (5.2%)
patients with bone or brain metastasis and one (2.6%)
with local recurrence. Follow up months ranged from 4
to 93 months, with a median of 47.5 months [mean of
45.6 months].
Discussion
There is controversy in the management of the lobular
intraepithelial neoplasia (LIN), namely atypical lobular
hyperplasia (ALH)/lobular carcinoma in situ (LCIS)
diagnosed by core needle biopsy without other prolifera-
tive lesions such as atypical ductal hyperplasia (ADH),
ductal carcinoma in situ (DCIS), or invasive carcinomas.
Some recommend excisional biopsy and others support
no excision. There is consensus amongst pathologists,
however, regarding the margin assessment of LIN on
excisional biopsy; it is not mandatory to report LIN at
the margin as in DCIS or invasive carcinoma and most
pathologists do not report LIN at the margin. Obtaining
a margin clear of LIN is not a surgical goal. Generally,
t h ep r e s e n c eo fL I Na tt h el u m p e c t o m ym a r g i ni s
regarded as irrelevant by most clinicians. The lack of
consensus on this topic is illustrated by the results of a
recent online survey by the American Society of Breast
D i s e a s e .T h es u r v e yp o s e dt h eq u e s t i o no fa p p r o p r i a t e
Figure 7 Mammogram. Magnified mediolateral view on
mammogram shows clustered pleomorphic calcifications without
associated mass, distortion, or other principal abnormality.
Pathology showed pleomorphic lobular carcinoma in situ (pLCIS).
Figure 8 Ultrasound. Ultrasound demonstrates a vague area of
focal shadowing and distortion without a discrete mass. Pathology
showed invasive lobular carcinoma.
Figure 6 E-cadherin stain. E-cadherin immunohistochemical stain
from the figure 5 is negative supportive of lobular differentiation.
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lumpectomy for invasive cancer. 40% of those who
replied stated that they would consider re-excision in
this circumstance and 8% stated that they would always
perform a re-excision. (Observation from American
Society of Breast Disease. ASBD Advisor 2008; Feb 17).
Also, unlike DCIS, patients with LIN alone on excision
are not treated with radiation after breast conservation
therapy unless there is a concomitant DCIS or invasive
carcinoma. With emerging new evidence that LIN is not
just a risk factor but a precursor lesion to invasive carci-
noma, margin status may play an important role in the
treatment of patients with LIN. If LIN is indeed a pre-
cursor lesion, then its presence at the surgical margin in
a lumpectomy specimen should increase local recur-
rence in patients treated with breast-conserving therapy.
In an attempt to test this hypothesis, we compared local
residual/recurrence rates in patients with and without
LIN at the margin who underwent breast conservation
surgery for the treatment of invasive carcinoma or
DCIS. Ideally, the positive and negative control groups
should have a similar disease process except for margin
status. The positive group included some cases that had
no cancer/DCIS, i.e. only LCIS, with LCIS/ALH at the
margin but the negative group did not have any cases
that had only LCIS/ALH in the specimen. This was
done so that our study would underestimate rather than
possibly overestimate the risk of having LIN at the mar-
gin, especially given the fact that it is clinically a short-
term follow-up.
As it is often difficult to differentiate between a local
recurrence and a new primary in the treated breast, all
tumor found in the ipsilateral breast during follow-up
were classified as local recurrences in our study. Techni-
cally it shouldn’t be considered as recurrences, but con-
sidered as residual tumor because the cancer was
probably there at the time of initial resection, and not
progressed from the margin LIN.
Our study showed 39% had significant recurrent dis-
eases when LIN was seen at the surgical margin of
initial breast conservation therapy, compared to 7.9%
from negative control group. This 7.9% includes patients
with metastasis in the negative group, but the 39% from
positive group counts only local recurrence.
There are limited numbers of LIN recurrence data
after only breast conservation therapy. The reported fre-
quencies of recurrence of invasive carcinoma after LCIS
diagnosis is approximately 10% and 20% of patients at
10 years and 20 years, respectively. The survival rate at
15 years was 100% in a cohort of 32 patients [6-8].
The NSABP B-17 study analyzed a subset of 182
patients with LCIS in addition to DCIS and treated with
breast conservation therapy alone was compared to
D C I Sa l o n ei nt h ei n c i d e n c eo fr e c u r r e n c e .T h ei p s i l a t -
eral recurrence of LCIS and DCIS was significantly
l o w e rt h a nD C I Sa l o n e ;2 . 2 %i nL C I Sa n dD C I Sa n d
12% in the DCIS alone respectively. Also, the contralat-
eral breast recurrence incidence was 1.1% compared to
9% respectively. Their conclusion was that the presence
of LCIS should not lead to more surgery such as mas-
tectomy [9].
A similar conclusion was drawn from Carolin K et al.
[10] study which compared LCIS and invasive cancer
group to invasive cancer without LCIS; there was no sig-
nificant increase in ipsilateral or contralateral breast
recurrence in a total of 105 patients with LCIS and 115
patients without LCIS. Over time, there was no increase
in relapse noted for the patients who had LCIS as a his-
tologic component of invasive carcinoma.
Jobsen et al. [11] looked at the impact of margin sta-
tus and outcome of invasive lobular carcinoma treated
with breast-conserving therapy and followed the long
term outcome from a single region in the Netherlands
during the last twenty years with 318 patients and 33
re-excision. They found that the positive margins for
ILC seem to be a strong predictor for local recurrence
in women less than or equal to 50 years of age but the
distant metastasis free survival and disease free survival
were not affected by the margin status. LCIS alone did
not show significance in relation to local control. Their
Figure 9 MRI. MRI demonstrates a large, irregular, enhancing mass with spiculated margins in the right breast. Pathology showed invasive
lobular carcinoma.
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r e n c er a t ew i t hp o s i t i v em a r g i n sf o rL C I So n l ya n dt h i s
seems limited to women greater than 50-years of age.
Robin M. Ciocca et al. [12] studied whether or not
LCIS at the margin would increase local recurrence in
patients treated with breast-conserving therapy. In their
84 patients with LCIS present at the specimen margin,
the crude rate of local recurrence for patients with and
without LCIS was 4.5% and 3.8% respectively. They con-
cluded that re-excision is not indicated even if LCIS is
present at the margin.
Jolly et al., [13] on the contrary, found that the pre-
sence of LCIS was associated with a higher incidence
ipsilateral recurrence; 14% with LCIS at the margin
when compared to 7% without LCIS at the margin
from a patient sample of 56 with a median of 8.7 years
follow up.
Stolier A et al. [14] reported no local recurrence with
LCIS in 40 patients with 38% involved or close margin
with LCIS in 67 months follow-up period. Ben-David M
et al. [15] reported that the presence of LCIS at the
margins and the multifocal extent of LCIS did not alter
the rate of local recurrence in their 64 patients’ samples
who received breast conservation and radiation treat-
ment with the median follow-up time of 3.9 years.
Abner et al. [16] reported similar results; that the extent
of LCIS and positive margin with LCIS did not have
increased local recurrence rate in 8 years. Sasson et al.
[17] reported that the ipsilateral local recurrence rate of
29% in the LCIS group as opposed to 6% in the gener-
ally treated population. However, when tamoxifen treat-
ment was used as hormonal therapy, the difference was
not significant; 8% as opposed to 6%, comparing the
LCIS group to the control group.
Literature supports that with the incidences of ipsilat-
eral and contralateral recurrence rates, mortality rates
are low with LIN, and even with invasive lobular carci-
noma. This may be due to the fact that the development
of invasive carcinoma after LIN takes a long time. Most
of the studies have a short median follow-up and cannot
exclude the possibility that, with a longer follow-up
duration, an impact of LIN on local recurrence will be
significantly increased. In fact, the study of Rosen et al.
reported the average interval to the development of can-
cer was 20.4 years after biopsy [18]. Another study by
Page et al. [19] showed 75% of cancers developed within
15 years of biopsy of LCIS.
Long term follow-up of LIN treated with BCT alone
has demonstrated a 1% per year cumulative long-term
risk of breast carcinoma persisting even 10-20 years
after diagnosis. Like most retrospective studies, the
inability to prospectively evaluate the conclusions and
hypotheses is a limiting factor, as well as a short term
follow up in LIN. Clinical follow-up of more than 5
years is needed to verify the significance of LIN in the
ipsilateral recurrence. Prospective randomized trials
related to therapy of patients with LIN at the margin
are needed to clearly understand the risk of local recur-
rence. However, a low mortality rate supports the view
that mastectomy is not indicated to clear LIN at the
margin if LIN is classic type and grade 1. If there is an
overlapping feature of LCIS with DCIS, then re-excision
is not unreasonable.
There is no doubt that LIN is a risk factor for subse-
quent carcinoma, and morphologic, immunohistochem-
ical and epidemiologic observations support the
statement that LIN is also a direct precursor to invasive
carcinoma. Although our data is limited due to the fact
that it is a retrospective study and small in sample size,
such data would only add to the limited number of LIN
recurrence rate after breast conservation therapy. The
limitation of our study is that there may be follow-up
bias. In our negative control group, there are not any
additional surgeries so we cannot be sure that there are
no cancerous lesions in the control group.
Conclusions
In order to better understand the local recurrence rate
to ipsilateral, contralateral, and systemic metastatic rate,
it would be important to include the description of mar-
gin status by LIN. Our data suggests that the adequacy
of the excision with LIN at the margin should be con-
sidered, and re-excision is recommended to decrease
recurrence rate (significant residual disease).
Additional material
Additional file 1: Diagnostic pathology. LCIS Table S1.
Additional file 2: Table S2: Diag pathol.
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